February 2022 FDA Recall Drug by The Harvard Drug Group
D-0653-2022 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by The Harvard Drug Group on February 24, 2022 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0653-2022

Reason for Recall
Failed Impurities/Degradation Specifications: Out of specification result obtained during routine stability testing for Impurities.
Initiated
02-24-2022
Reported
03-23-2022
Quantity
5,953 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
The Harvard Drug Group
Nationwide within USA
hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61

Batch or Lot Expiration Information

Lot# : T03755, T03756, Exp. Date 03/2023